Optimization of third-stage management after second-trimester medical pregancy termination

American Journal of Obstetrics and Gynecology

Volumn 201, Issue 3, 2009, Pages 303.e1-303.e7

  Dickinson, Jan E ^a   Doherty, Dorota A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

medical termination; misoprostol; placenta; third stage

Indexed keywords

MISOPROSTOL; OXYTOCIN;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HUMAN; LABOR MANAGEMENT; LABOR STAGE 3; MAJOR CLINICAL STUDY; MANUAL PLACENTAL DELIVERY; PREGNANCY TERMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETAINED PLACENTA; SECOND TRIMESTER PREGNANCY; SINGLE DRUG DOSE; SURVIVAL;

EID: 69349098631     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.05.044     Document Type: Article

References (16)

1. Lalitkumar S., Bygdeman M., and Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update 13 (2007) 37-52
2. Ho P.C., Blumenthal P.D., Gemzell-Danielsson K., et al. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 99 Suppl 2 (2007) S178-S181
3. von Hertzen H., Piaggio G., Wojdyla D., et al. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Hum Reprod 24 (2009) 106-112
4. Dickinson J.E., and Evans S.F. A comparison of oral with vaginal administration of misoprostol in second trimester termination for fetal anomaly. Obstet Gynecol 101 (2003) 1294-1299
5. Ashok P.W., Templeton A., Wagaarachchi P.T., and Flett G.M.M. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 69 (2004) 51-58
6. Dodd J., and Crowther C.A. Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. Eur J Obstet Gynecol Reprod Biol 125 (2006) 3-8
7. Dickinson J.E., and Doherty D.A. Factors influencing the duration of pregnancy termination with vaginal misoprostol for fetal abnormality. Prenat Diagn 29 (2009) 520-524
8. Carlan S.J., Gushwa J.P., O'Brien W.F., and Vu T. Effect of intramuscular 15-methyl prostaglandin F2α. Obstet Gynecol 89 (1997) 5-9
9. Leader J., Bujnovsky M., and Carlan S. Effect of oral misoprostol after second-trimester delivery: a randomized, blinded study. Obstet Gynecol 100 (2002) 689-694
10. Bhattacharjee N., Saha S.P., Ghoshroy S.C., Bhowmik S., and Barui G. A randomized comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. Aust N Z J Obstet Gynaecol 48 (2008) 165-171
11. Dickinson J.E., and Evans S.F. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 186 (2002) 470-474
12. Rodger M.W., and Baird D.T. Pretreatment with mifepristone (RU486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. Br J Obstet Gynaecol 97 (1990) 41-45
13. Lohr P.A., Hayes J.L., and Gemzell-Danielsson K. Surgical versus medical methods for second trimester induced abortion. Cochrane Database Syst Rev 1 (2008) CD006714
14. Green J., Borgatta L., Sia M., Kapp N., Saia K., Carr-Ellis S., and Vragovic O. Intervention rates for placental removal following induction abortion with misoprostol. Contraception 76 (2007) 310-313
15. Sundaram S., Diaz J.P., Gonzalez-Quintero V.H., and Verma U. Rectal misoprostol vs 15-methyl prostaglandin F2α for retained placenta after second trimester delivery. Am J Obstet Gynecol 200 (2009) e24-e26
16. Carbonell J.L., Torres A., Reyes R., Ortega L., García-Gallego F., and Sánchez C. Second-trimester pregnancy termination with 600-μg vs. 400-μg vaginal misoprostol and systematic curettage postexpulsion: a randomized trial. Contraception 77 (2008) 50-55